PMID- 10190900
OWN - NLM
STAT- MEDLINE
DCOM- 19990506
LR  - 20190508
IS  - 0022-1007 (Print)
IS  - 0022-1007 (Linking)
VI  - 189
IP  - 7
DP  - 1999 Apr 5
TI  - A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed 
      on all natural killer cells.
PG  - 1093-100
AB  - Human natural killer (NK) cells express several killer cell immunoglobulin
      (Ig)-like receptors (KIRs) that inhibit their cytotoxicity upon recognition of
      human histocompatibility leukocyte antigen (HLA) class I molecules on target
      cells. Additional members of the KIR family, including some that deliver
      activation signals, have unknown ligand specificity and function. One such KIR,
      denoted KIR2DL4, is structurally divergent from other KIRs in the configuration
      of its two extracellular Ig domains and of its transmembrane and cytoplasmic
      domains. Here we show that recombinant soluble KIR2DL4 binds to cells expressing 
      HLA-G but not to cells expressing other HLA class I molecules. Unlike other HLA
      class I-specific KIRs, which are clonally distributed on NK cells, KIR2DL4 is
      expressed at the surface of all NK cells. Furthermore, functional transfer of
      KIR2DL4 into the cell line NK-92 resulted in inhibition of lysis of target cells 
      that express HLA-G, but not target cells that express other class I molecules
      including HLA-E. Therefore, given that HLA-G expression is restricted to fetal
      trophoblast cells, KIR2DL4 may provide important signals to maternal NK decidual 
      cells that interact with trophoblast cells at the maternal-fetal interface during
      pregnancy.
FAU - Rajagopalan, S
AU  - Rajagopalan S
AD  - Laboratory of Immunogenetics, National Institute of Allergy and Infectious
      Diseases, National Institutes of Health, Rockville, Maryland 20852, USA.
FAU - Long, E O
AU  - Long EO
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immune Sera)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (KIR2DL4 protein, human)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, KIR)
RN  - 0 (Receptors, KIR2DL4)
RN  - 0 (Receptors, KIR2DL5)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
EIN - J Exp Med 2000 Jun 5;191(11):following 2027
MH  - Cell Membrane/chemistry
MH  - Cytotoxicity, Immunologic
MH  - Female
MH  - Fetus/immunology
MH  - HLA Antigens/genetics/*immunology/metabolism
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/genetics/*immunology/metabolism
MH  - Humans
MH  - Immune Sera
MH  - Immunoglobulin Fc Fragments/genetics
MH  - Killer Cells, Natural/*immunology
MH  - Pregnancy
MH  - Protein Binding
MH  - Receptors, Immunologic/analysis/genetics/*immunology
MH  - Receptors, KIR
MH  - Receptors, KIR2DL4
MH  - Receptors, KIR2DL5
MH  - Recombinant Fusion Proteins/immunology/metabolism
MH  - Signal Transduction
MH  - Solubility
MH  - Transcription, Genetic
MH  - Transfection
MH  - Trophoblasts/*immunology
PMC - PMC2193010
EDAT- 1999/04/06 00:00
MHDA- 1999/04/06 00:01
CRDT- 1999/04/06 00:00
PHST- 1999/04/06 00:00 [pubmed]
PHST- 1999/04/06 00:01 [medline]
PHST- 1999/04/06 00:00 [entrez]
AID - 10.1084/jem.189.7.1093 [doi]
PST - ppublish
SO  - J Exp Med. 1999 Apr 5;189(7):1093-100. doi: 10.1084/jem.189.7.1093.